# Safety and Antiviral Activity Study of Clevudine 30 mg QD in Patient With Chronic HBV

> **NCT00313287** · PHASE3 · TERMINATED · sponsor: **Bukwang Pharmaceutical** · enrollment: 180 (—)

## Conditions studied

- Hepatitis B

## Interventions

- **DRUG:** clevudine

## Key facts

- **NCT ID:** NCT00313287
- **Lead sponsor:** Bukwang Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2003-06
- **Primary completion:** —
- **Final completion:** 2004-11
- **Target enrollment:** 180 (—)
- **Last updated:** 2017-02-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00313287

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00313287, "Safety and Antiviral Activity Study of Clevudine 30 mg QD in Patient With Chronic HBV". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT00313287. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*